Young Ho Ko

Young Ho Ko

Auto-generated profile, based on publicly available information

Young Ho Ko

Institute for Basic Science

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2018 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
KPKyeng Min Park
Kyeng Min Park
KBKangkyun Baek
Kangkyun Baek
YKYoung Ho Ko
Young Ho Ko
SAShrinidhi Annadka
Shrinidhi Annadka
JMJames Murray
James Murray
KKKimoon Kim
Kimoon Kim

21 February 2018 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
KPKyeng Min Park
Kyeng Min Park
KBKangkyun Baek
Kangkyun Baek
YKYoung Ho Ko
Young Ho Ko
ASAnnadka Shrinidhi
Annadka Shrinidhi
JMJames Murray
James Murray
KKKimoon Kim
Kimoon Kim

Verified
Journal Article
Open access
PDF file
BKBokyung Kim
Bokyung Kim
YKYoung Ho Ko
Young Ho Ko
Massimiliano RunfolaMassimiliano Runfola
Massimiliano Runfola
Simona RapposelliSimona Rapposelli
Simona Rapposelli
GOGabriella Ortore
Gabriella Ortore
Jin Hae KimJin Hae Kim
Jin Hae Kim
Thyromimetics, whose physicochemical characteristics are analog to thyroid hormones (THs) and their derivatives, are promising candidates as novel therapeutics for neurodegenerative and metabolic pathologies. In particular, sobetirome (GC-1), one of the initial halogen-free thyromimetics, and newly synthesized IS25 and TG68, with optimized ADME-Tox profile, have recently attracted attention owing to their superior therapeutic benefits, selectivity, and enhanced permeability. Here, we further explored the functional capabilities of these thyromimetics to inhibit transthyretin (TTR) amyloidosis. TTR is a homotetrameric transporter protein for THs, yet it is also responsible for severe amyloid fibril formation, which is facilitated by tetramer dissociation into non-native monomers. By combining nuclear magnetic resonance (NMR) spectroscopy, computational simulation, and biochemical assays, we found that GC-1 and newly designed diphenyl-methane-based thyromimetics, namely IS25 and TG68, are TTR stabilizers and efficient suppressors of TTR aggregation. Based on these observations, we propose the novel potential of thyromimetics as a multi-functional therapeutic molecule for TTR-related pathologies, including neurodegenerative diseases.

20 February 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
YYYelim Yi
Yelim Yi
BKBokyung Kim
Bokyung Kim
YKYoung Ho Ko
Young Ho Ko
Jin Hae KimJin Hae Kim
Jin Hae Kim
MLMi Hee Lim
Mi Hee Lim
Extracellular accumulation of amyloid-beta (Abeta) peptides in the brain plays a significant role in the development of Alzheimer's disease (AD). While the co-localization and interaction of proteins and metal ions with Abeta in extracellular milieu are established, their precise pathogenic associations remain unclear. Here we report the impact of Zn(II) on the anti-amyloidogenic properties of monomeric transthyretin (M-TTR), which coexists spatially with Abeta and Zn(II) in extracellular fluids. Our findings demonstrate the Zn(II)-promoted ternary complex formation involving M-TTR, Abeta40, and Zn(II) as well as M-TTR's proteolytic activity towards Abeta40. These interactions alter the inhibitory effect of M-TTR on Abeta40 amyloidogenesis, particularly affecting the primary nucleation process, and mitigate the cytotoxicity induced by Abeta40. This study unveils the variable activities of M-TTR towards Abeta40, driven by Zn(II), providing insights into how metal ions influence the entanglement of M-TTR in the Abeta-related pathology linked to AD.